Expression, Role, and Regulation of Neutrophil Fcγ Receptors
Yu Wang, Friederike Jönsson

To cite this version:
Yu Wang, Friederike Jönsson. Expression, Role, and Regulation of Neutrophil Fcγ Receptors. Frontiers in Immunology, Frontiers, 2019, 10, pp.1958. 10.3389/fimmu.2019.01958. pasteur-02348451

HAL Id: pasteur-02348451
https://hal-pasteur.archives-ouvertes.fr/pasteur-02348451
Submitted on 5 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Expression, Role, and Regulation of Neutrophil Fcγ Receptors

Yu Wang1,2 and Friederike Jönsson1*

1 Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, Paris, France, 2 Université Diderot Paris VII, PSL University, Paris, France

Neutrophils are best known for their critical role in host defense, for which they utilize multiple innate immune mechanisms, including microbe-associated pattern recognition, phagocytosis, production of reactive oxygen species, and the release of potent proteases, mediators, antimicrobials, and neutrophil extracellular traps. Beyond their well-established contribution to innate immunity, neutrophils were more recently reported to interact with various other cell types, including cells from the adaptive immune system, thereby enabling neutrophils to tune the overall immune response of the host. Neutrophils express different receptors for IgG antibodies (Fcγ receptors), which facilitate the engulfment of IgG-opsonized microbes and trigger cell activation upon cross-linking of several receptors. Indeed, FcγRs (via IgG antibodies) confer neutrophils with a key feature of the adaptive immunity: an antigen-specific cell response. This review summarizes the expression and function of FcγRs on human neutrophils in health and disease and how they are affected by polymorphisms in the FCGR loci. Additionally, we will discuss the role of neutrophils in providing help to marginal zone B cells for the production of antibodies, which in turn may trigger neutrophil effector functions when engaging FcγRs.

Keywords: neutrophils, Fcγ receptors, IgG, immune complexes, B cells

INTRODUCTION

Neutrophils are key players of the innate immune response. They are the most abundant leukocytes in the human blood (4.5–11 × 103/mm3). Following a circadian rhythm, neutrophils are released from the bone marrow (1–3) and circulate in the blood for 4–6 days (4, 5). If they are not attracted to sites of inflammation, they will express markers of aged neutrophils, and preferentially home to the liver, spleen, or bone marrow, where they undergo apoptosis and are cleared by resident macrophages (6–8). This immunologically silent mechanism allows for maintaining a high number of functional neutrophils in the blood (55–70% of all blood leukocytes in the periphery), while guaranteeing a quick removal of deregulated or altered neutrophils. The tight control of neutrophil homeostasis is critical for the organism as many of their effector functions [i.e., production of reactive oxygen species (ROS), release of neutrophil extracellular traps (NETs), or granules containing potent proteases and lipophosphatases (9)] bare the potential to be deleterious for the host and damage surrounding tissues and organs.

Neutrophils express various receptors that enable them to respond almost instantaneously to diverse inflammatory stimuli and danger signals. Among these, receptors for the constant region of IgG immunoglobulins (FcγRs) stand out. They bestow on neutrophils the capacity to react in an antigen-specific way—hence to acquire a key feature of the adaptive immunity. FcγRs enable neutrophils to interact with and respond to monomeric or aggregated immunoglobulins,
antigen–antibody immune complexes, and opsonized (antibody-coated) particles, cells, or surfaces. Humans express six classical FcγRs: FcγRI/CD64, FcγRIIA/CD32A, FcγRIIB/CD32B, FcγRIIIC/CD32C, FcγRIIIA/CD16A, and FcγRIIIB/CD16B (Table 1). All these FcγRs bind at least two of the four different human IgG subclasses with association constants (K_\text{A}) ranging from 8 × 10^7 to 2 × 10^4 M^{-1} (10).

All FcγRs, except for FcγRIIB and FcγRIIIA, are classical activating receptors. Their activating signals are transduced by an immunoreceptor tyrosine-based activation motif (ITAM) that is either present in the cytoplasmic domain of the FcγR itself (FcγRIIA/FcγRIIC) or in an associated signaling subunit, notably the FcγR chain. Upon FcγR aggregation by multimeric ligands, Src family kinases phosphorylate these motifs, allowing the activation of a signaling cascade, involving the spleen tyrosine kinase (SYK), phosphatidylinositol 3-kinase (PI3K), phospholipase C (PLC)–γ, Rho, and Rac, resulting in calcium mobilization, cell activation, cytokine/chemokine production, and cell migration (11–13). Counterbalancing these activating FcγRs, the inhibitory receptor FcγRIIB possesses an immunoreceptor tyrosine-based inhibition motif (ITIM) in its intracytoplasmic domain. Upon its co-engagement with an activating receptor, the phosphorylated ITIM recruits the inositol polyphosphate-5-phosphatase SHIP1 (14) that negatively regulates the signaling cascades initiated by ITAM-containing receptors (15–17). Moreover, several FCGR polymorphisms have been described in humans, adding to the complexity of this receptor family with overlapping functions and affinities for their ligands that collaborate, regulate, or compete with each other to tune cellular responses.

In this review, we will focus on IgG receptors (FcγRs) on neutrophils and their role and regulation in steady state and inflammatory conditions.

### EXPRESSION AND ROLE OF FcγR ON NEUTROPHILS DURING HOMEOSTASIS

Blood neutrophils from healthy individuals express large amounts of a rather atypical FcγR, the FcγRIIB. FcγRIIB is a glycophasphotidylinositol (GPI)-anchored protein with no signaling capacity on its own. It was first described on neutrophils in 1982 with the means of a newly developed monoclonal antibody (mAb, 3G8) that also recognizes FcγRIIA on monocytes and NK cells (18). Incubation of neutrophils with 3G8 could efficiently block binding of rabbit IgG-opsonized sheep erythrocytes and soluble rabbit IgG immune complexes (ICs), demonstrating that the newly identified receptor is an IgG Fc receptor (18). FcγRIIB is one of the most abundant proteins on the surface of neutrophils, with each cell expressing between 100,000 and 200,000 copies (19). In resting neutrophils, the receptor is equally distributed over the cell membrane and is present in both low- and high-density detergent-resistant membranes (DRMs) (20). Additionally, intracellular storage compartments have been described that allow rapid FcγRIIB mobilization to the cell surface upon receptor engagement (21, 22). Previously thought to have no signaling function, it is now generally accepted that FcγRIIB can trigger neutrophil activation. Following multivalent cross-linking, FcγRIIB accumulates in high-density DRMs (20) and elicits downstream signals, leading to Ca^{2+} mobilization, cell adhesion, and degranulation, but not to respiratory burst (23–27). The exact intracellular signaling cascade remains a matter of debate (20, 27–29), but seems to involve phosphorylation of the Src kinase Hck, mitogen-activated kinases (MAPKs) ERK (extracellular signal regulated kinase), and p38 and the tyrosine kinase Pyk2 (30–32). In this context, it is noteworthy that the 3G8 antibody, which is often used to block FcγRIIB, can trigger

### TABLE 1 | Classical FcγRs and their expression on neutrophils.

| Name | FcγRI | FcγRIIA | FcγRIIB | FcγRIIC | FcγRIIIA | FcγRIIIB |
|------|-------|---------|---------|---------|----------|---------|
| CD   | CD64  | CD32A   | CD32B   | CD32C   | CD16A    | CD16B   |
| Gene | FCGR1A | FCGR2A  | FCGR2B  | FCGR2C  | FCGR3A   | FCGR3B  |
| Alleles | – | H\text{131} R\text{131} | I\text{132} T\text{132} | Q\text{27} stop\text{57} | V\text{176} F\text{176} | NA1 NA2 SH |
| Affinity | High | Low to medium | Low to medium | Low to medium | Low to medium | Low to medium |
| Expression on resting neutrophils | Low to none Low to none Low to none Up to 10-fold increased expression in presence of IFN-γ and G-CSF |
| Neutrophil expression in inflammatory conditions | Low to none Low to none Low to none Upregulated in presence of TNF-α |

Frontiers in Immunology | www.frontiersin.org 2 August 2019 | Volume 10 | Article 1958

Wang and Jönsson Neutrophil Fcγ Receptors
intracellular Ca-mobilization and neutrophil aggregation on its own. This cell activation requires co-engagement of another neutrophil FcγR, FcγRIIA via the Fc portion of the intact antibody (33). The main functions of neutrophil FcγRIIB during homeostasis are the removal of spontaneously forming ICs from the vasculature, and the maintenance of the soluble FcγRIIB (sFcγRIIB) pool. FcγRIIB-bound ICs are internalized through a mechanism used by GPI-anchored receptors and fluid-phase endocytosis (27), thereby clearing ICs without triggering further cell activation that could be deleterious to the host. sFcγRIIB is present in serum of healthy individuals at concentrations of 5 nM (34). It is generated by proteolytic cleavage of surface FcγRIIB on activated and apoptotic neutrophils (34, 35). Despite its relative abundance, the function of sFcγRIIB remains elusive. sFcγRIIB retains Fc-binding capacities and hence competes with membrane low-affinity receptors to dampen Fc-dependent immune reactions (36, 37). Due to the fact that FcγRIIB binds to multimeric IgG1 and IgG3, but not or poorly IgG2 or IgG4 (10), the biological activity of these latter IgG subclasses should not be affected by sFcγRIIB. Notably, both IgG2 and IgG4 also bind less well to other low-affinity FcRs (with the exception of FcγRIIA-H131) (10). Adding to this possible immune-modulatory function, it also has been reported that sFcγRIIB can bind to complement receptors CD11b/CD18 or CR3/Mac-1 and CD11c/CD18 or CR4 via lectin/carbohydrate interactions (38). These interactions can result in cytokine production by neutrophils and monocytes or may inhibit β2 integrin-dependent adhesion and subsequent transendothelial migration (38).

Neutrophils constitutively express a second low-affinity IgG receptor, the FcγRIIA. Albeit less abundant than FcγRIIB, neutrophil expresses between 30,000 and 60,000 copies of FcγRIIA (19). Interestingly, this receptor was described to have a lower affinity for IgG on resting than on primed or activated neutrophils (39), a feature that has been attributed to its interactions with integrins (40). Upon efficient cross-linking of FcγRIIA in vitro, neutrophils become activated, degranulate, and produce inflammatory mediators and ROS and trigger neutrophil extracellular trap (NET) formation (27, 41–44). More recent data, however, suggest that resting neutrophils rather poorly respond to FcγRIIA-induced activation. One possible explanation for these divergent observations may be found in the purification techniques used to isolate neutrophils. Indeed, density gradient centrifugation or dextran sedimentation used to be the standard techniques. Nowadays, neutrophils are mostly isolated by negative selection procedures that maintain the cells in isotonic buffer, but expose them to magnetic fields. Indeed, while comparative data between the procedures are sparse (45, 46), possible differences in neutrophil priming and purity need to be taken into account when interpreting the data.

In contrast to the abundant FcγRIIB and FcγRIIA, neutrophils express less than 2,000 copies of the high-affinity FcγRI (19). Ligation of FcγRI on resting neutrophil with a specific antibody does not induce a significant degree of cell activation (47) and neutrophils show poor binding to monomeric IgG1 and phagocytosis of IgG-opsonized particles (48, 49). Neutrophils can also express FcγRIIB; however, its detection is variable among individuals ranging from low to undetectable (27, 50).

Although it is well-established that co-engagement of FcγRIIB potently inhibits FcγR-driven cell activation (15–17), it is questionable if the low expression of FcγRIIB on neutrophils could oppose signals generated by the other FcγRs in this context. Finally, a very recent report suggests that neutrophils may also express modest amounts of FcγRIIA (51), a receptor that was previously thought to be exclusively expressed by NK cells and monocytes (52). In this study, the authors report that FcγRIIA engagement on neutrophils from FcγRIIB-deficient and normal individuals efficiently triggers cell activation and mediates phagocytosis of IgG-opsonized beads that could not be blocked by anti-FcγRIIA F(ab′)2 fragments (51). Many different groups have studied FcγR expression on neutrophils before, but were incapable to affirm FcγRIIA expression. This might be due to the fact that most antibodies used to study FcγRII recognize both FcγRIIA and FcγRIIB, and that FcγRIIB deficiency is rare. In a study from 1994, one can however appreciate some residual FcγRII [3G8] staining on neutrophils from paroxysmal nocturnal hemoglobinuria patients [a disorder characterized by the deficiency of glycosyl phosphatidylinositol (GPI)-anchored proteins in blood cell membranes] and an FcγRIIB-deficient patient, as well as on neutrophils treated with GPI-phospholipase C as compared to an isotype control (53). This residual binding, if specific, could support the hypothesis of a low expression of FcγRIIA on neutrophils. The central piece of evidence for FcγRIIA expression on neutrophils in the recent report is a single FcγRIIB-deficient donor, whose genotype was confirmed by RT-PCR and not by sequencing of the FcγR locus. This allows speculation about a cryptic FcγRIIB expression in this donor. Furthermore, if a low expression of FcγRIIA can be confirmed in other FcγRIIB-deficient donors, it will be necessary to clarify to what extent it can contribute to neutrophil effector functions in vivo. One point is certain, this study refuels the discussion about the capacity of FcγRIIB to trigger cell activation and suggests that neutrophil activation observed following receptor cross-linking with anti-FcγRII F(ab′)2 fragments or ICs can be rather attributed to FcγRIIA than to the GPI-anchored receptor.

**NEUTROPHIL FCγR IN AN INFLAMMATORY CONTEXT**

Neutrophil FcγR expression can change dramatically in the context of an inflammation or infection. Notably, FcγRI is strongly upregulated in the presence of inflammatory cytokines such as interferon-γ (IFN-γ) or granulocyte colony-stimulating factor reaching up to 20,000 copies per cell (19, 48, 54, 55). This confers neutrophils the capacity to efficiently bind monomeric IgG (48), phagocyte IgG-opsonized bacteria (49), exert antifungal functions (56), and induce ROS production in response to FcγR cross-linking (47). FcγRI upregulation also enables neutrophils to efficiently trigger antibody-dependent cytotoxicity (ADCC) (55). As a consequence, neutrophil FcγRI expression has been shown to reflect infection state and disease activity in numerous inflammatory conditions (57–61), and a low CD64 expression is a marker for sustained remission in Crohn’s disease patients receiving infliximab (62). Consecutively, neutrophil
CD64 has been discussed as an interesting biomarker, especially in the case of sepsis (57). Sepsis diagnosis includes a blood culture that allows specific identification of the disease-causing bacteria and their antibiotic resistances, but takes up to 2 days to generate results. Precious time, during which patients with sepsis suspicion commonly receive broad-spectrum antibiotics to avoid deterioration of their condition. This common practice has its flaws, because antibiotics are not adapted in case of non-bacterial infections, and because some bacteria require specific antibiotics and are not targeted by broad-spectrum ones. Certainly, inappropriate use of antibiotics contributes to the increase of antibiotic resistance among different bacteria that has been classified as “one of the biggest threats to global health, food security, and development today” by the WHO. Neutrophil CD64 expression was proposed as a way to detect infection so that timely decisions and treatment refinement can be made. Neutrophil CD64 can be evaluated within 1–2 h, making it a rapid diagnostic and prognostic marker. Indeed, a study reported not only elevated CD64 expression in septic patients compared to healthy controls, but also a decrease in CD64 expression following treatment with an appropriate antibiotic compared to inefficient treatment (63). However, not all studies find in neutrophil CD64 a reliable marker for sepsis detection, and different studies report divergent sensitivity and specificity for sepsis detection by neutrophil CD64 (64–67). Two meta-analyses report a large heterogeneity in study design and results (68, 69). This may be due to the fact that this test can be run in any laboratory with a flow cytometer and that the results can be expressed either as percentage of neutrophils expressing CD64 or as mean fluorescent intensity of the whole neutrophil population. In the absence of a standardized assay, each laboratory needs to establish its own cutoff. Furthermore, confounding factors (previous use of antibiotics, delayed culture collection, etc.) may result in a negative result from the microbiological test that, as a consequence, poses problems with the classification of the patients. Given the low costs of the assay, neutrophil CD64 remains an interesting candidate to monitor in case of sepsis suspicion. Larger prospective studies are however required to conclude on its sensitivity and suitability as a biomarker, especially in light of new approaches for sepsis diagnosis and the evolution of our understanding of sepsis as a condition involving not only the bacterial infection and its resulting immune response, but also changes in coagulation, immunosuppression, and organ dysfunction (70).

IFN-γ treatment has little effect on neutrophil FcγRIIA expression but can induce FcγRIIB expression (albeit on a low level) and, depending on the experimental conditions, may induce FcγRIIB down-modulation (19, 71). FcγRIIA expression on neutrophils may however be induced by TNF-α (72). As a consequence, primed neutrophils and neutrophils from individuals with inflammatory conditions show enhanced FcγR-dependent responses (73–75).

Finally, IgG ICs can also be at the onset of inflammation, allergic reactions, and autoimmunity (76, 77). This is notably the case, when the amounts of circulating ICs suddenly rise and exceed the body’s capacity to silently remove them, when ICs form that are insoluble and “precipitate” onto endothelial cells, or when autoantibodies bind to large surfaces, i.e., cartilage, thereby opsonizing phagocytosis-resistant structures. All these conditions can be mimicked in vitro and helped to understand that soluble ICs require primed neutrophils to efficiently trigger external ROS production and degranulation, while insoluble ICs can activate unprimed neutrophils, leading to intracellular ROS production, degranulation, and sustained liberation of inflammatory mediators such as IL-8 and leukotriene B4 (LTB4) that sustain neutrophil-driven inflammation (73, 78). An elegant study, using transgenic mice expressing either FcγRIIA or FcγRIIB or both in the absence of endogenous activating FcγR, demonstrated that FcγRIIB has a primordial role in the homeostatic removal of soluble ICs within the vasculature, whereas FcγRIIA engagement by soluble ICs in tissues generates NETs, a pro-inflammatory process linked to autoimmunity (27, 44). Engagement of either FcγR by deposited ICs leads to neutrophil accumulation (44). These data illustrate the specialized role of FcγRs in triggering neutrophil effector functions, despite their overlapping binding properties to IgG.

GENETIC VARIATIONS AFFECTING NEUTROPHIL FcγR EXPRESSION AND FUNCTIONS

A number of polymorphisms have been identified in the FCGR loci that affect their biological functions and may consequently impact the individual’s susceptibility for diseases and their capacity to respond to therapies based on monoclonal antibodies. This is notably the case for polymorphisms that alter the affinity of FcγRs for IgG, thus directly affecting their capacity to clear immune complexes.

Until today, no polymorphism of FcγRI has been identified that modifies the affinity of the receptor for IgG or its associated functions. In contrast, the low-affinity IgG receptor locus on chromosome 1q23.3 coding for all FCGR2/3 genes is home to multiple genetic variants, including single-nucleotide polymorphisms (SNPs) and copy number variations (CNVs). These genetic variants display heterogeneity among ethnic groups (79). The best-characterized polymorphism of FCGR2A results in substitution of an arginine residue by a histidine at position 131 (rs1801274) that results in a receptor variant with an improved binding to IgG2 (and to a lesser extent to IgG1 and IgG3) (80). The FCGR2A-R131 variant is therefore expected to show lower clearance of IgG immune complexes and is indeed associated with susceptibility to auto-immune disorders (81–85) and recurrent bacterial infections with encapsulated bacteria (86). The FCGR2A-H131 variant, on the other hand, predisposes individuals to Kawasaki disease and Myasthenia gravis (87, 88). More recently, a splice variant of FCGR2A, FcγRIIA(exon6*), has been described that retains a cryptic exon in the cytoplasmic tail of the receptor (89, 90). This results in a gain-of-function allele that increases neutrophil sensitivity to IgG stimulation and hence predisposes to anaphylactic reactions following IVIg infusions in patients with hypogammaglobulinemia (71). As described above, FcγRIIB is poorly expressed on neutrophils (50). A specific haplotype in the promoter region, termed 2B,4,
was shown to augment FcγRIIB expression on myeloid cells, including neutrophils (91). This promoter variant enables a more efficient binding of the transcription factors GATA4 and Yin-Yang1, resulting in a higher promoter activity and hence higher FcγRIIB expression (92). Surprisingly, this gain-of-function promoter haplotype was found to be associated with systemic lupus erythematosus (SLE) (91). A possible explanation might reside in an FcγRIIB-dependent inhibition of IC-phagocytosis, but experimental data to support this hypothesis are still missing. Additionally, a polymorphism of FCGR2B (rs1050501) results in the replacement of a threonine in an isoleucine in the transmembrane domain (I232T). The presence of threonine in that position entails a failure of FcγRIIB to enter lipid rafts and, as a consequence, reduces its ability to inhibit activatory receptors (93). For FCGR3B, three different allotypes have been described, resulting from five non-synonymous polymorphisms that are all distinct Fy antigens (NA) located in the membrane-distal Ig-like domain. These variants are termed NA1 (R36 N65 A78 D82 Y106), NA2 (S36 S65 A78 N82 I106), and SH (S36 S65 D78 N82 I106) (94). They do not result in detectable differences in affinity for hIgG subclasses (10). The NA1 allotype was nevertheless reported to increase phagocytosis of IgG-opsonized particles (95) and is associated with a reduced responsiveness to IVIG therapy in Kawasaki disease (96). The SH allotype is the rarest allele and less well-characterized. Recently, it has been reported to be associated to increased FCGR3B copy numbers (79) that could account for the higher FcγRIIB expression levels described earlier (97).

A rather large number of studies have associated a single FcγR polymorphism with the induction or severity of antibody-related diseases, or the efficacy of antibody-based therapies. It is however important to bear in mind that all low-affinity IgG receptors are encoded in a single locus on chromosome 1 (1q23). Indeed, a high degree of linkage disequilibrium has been detected in the promoter region of the FCGR2A/2C and FCGR3A/3B loci (93). For FcγRs, several CNVs have been described that can influence the expression level of the receptors (97). These CNVs can include deletions of parts of the loci, giving rise to FCGRA2A/2C chimeric genes, reducing the expression and function (ROS induction) of the resulting receptor (101). CNVs of FCGR3B have been associated to a number of autoimmune disorders, including SLE, rheumatoid arthritis, and systemic auto- immunity (102–106). Indeed, fewer than two copies of FCGR3B have been associated to SLE susceptibility (107, 108), which has been confirmed in meta-analysis (109, 110).

Lastly, 0.03–0.1% of the population show a deficiency of FCGR3B (and the FCGRC2 gene) (101, 107). While most studies did not find an association of the FCGR3Bnull genotype with a disease phenotype, one report suggested an association with SLE (102, 111, 112). This apparent contradiction with the finding that low copy numbers increase SLE susceptibility could be due to the low frequency of this genotype in the population, resulting in an insufficient power for calculation.

On the other hand, FcγRIIIB-deficient individuals were included at the estimated frequency in a selective cohort of healthy donors with a long list of exclusion criteria, suggesting that FcγRIIIB deficiency remains undetected in most carriers (113). This suggests that FCGR3B deficiency does not directly cause disease, but possibly aggravates disease pathogenesis when ICs are accumulating.

**REGULATION OF NEUTROPHIL FcγRS**

The best-described pathway of inhibiting activating FcγRs is, without doubt, through co-engagement of the inhibitory FcγRIIB by the same immune complexes (114, 115). However, as mentioned earlier, human neutrophils express little to no FcγRIIB (50), and it appears therefore mandatory that neutrophils rely on other mechanisms to regulate their activation by FcγRs.

Recently, several groups have reported that the glycosylation state of the IgG antibodies significantly modifies their affinity for FcγRs (116–118). Indeed, all human IgG contain a single N-linked glycan positioned at asparagine 297 in the antibody Fc portion, which is critical for their interaction with FcγRs. Several studies have illustrated how the composition of the Fc glycan influences IgG effector functions (119, 120) (Figure 1A). As an example, IgG Fc glycans lacking fucose display a greatly enhanced affinity to the FcγRs, FcγRIIA, and FcγRIIB, compared to fucosylated IgG. Besides their well-established improvement of NK cell-dependent ADCC in vivo (121–123), afucosylated IgG used to opsonize target cells also activate neutrophils more efficiently than wild-type IgG, inducing pro-inflammatory cytokines and phagocytosis of target cells, but no ROS production or antibody-dependent cellular cytotoxicity activity (124). Addition of an afucosylated anti-CD20 mAb (obinutuzumab) to blood samples from RA and SLE patients resulted in a superior B cell deletion than wt anti-CD20 mAb, concomitantly with neutrophil and NK cell activation (125), suggesting that both cells cooperate to eliminate target cells in vitro. Opposing these results, another study reported FcγRIIB-dependent inhibition of neutrophil ADCC or trogocytosis of solid cancer cells coated with either anti-HER2 (mAb trastuzumab) or anti-EGFR mAb (cetuximab). Notably, copy numbers of FcγRIIB could be linked to the inhibitory effect and blocking FcγRIIB with F(ab’2) 3G8 improved target cell killing (126). Further studies are required to determine whether these discrepancies depend on the target cell (solid tumor vs. hematological) and how neutrophil FcγRIIB (and FcγRIIA) (51) contribute to cancer elimination in vivo. Terminal sialylation of the Fc glycan, instead, decreases the affinity for activating FcγRs (while maintaining the affinity for inhibitory FcγRIIB), and sialylated IgG has reduced capacity to initiate ADCC in vivo (118, 127). This might explain why antibodies against autoantigens can often be detected months to years before the first sign of an autoimmune inflammation (128–130). De-sialylation of these antibodies might therefore be a hallmark of autoimmune disease progression (131, 132). In this context, it is noteworthy that a recent report evidenced the potential of in vivo glycan engineering of antibodies to...
FIGURE 1 | Schematic representation of proposed mechanisms that regulate FcyR activity on neutrophils. (A) IgG glycosylation determines its affinity for FcyRs, (B) Mac-1 regulates FcyRIIA affinity for IgG, (C) CD300a-mediated FcyRIIA inhibition, (D) C-reactive protein (CRP)-driven FcyRIIA down-regulation, (E) FcyRIIB shedding by ADAM17, and (F) Interplay between Toll-like receptors (TLR)7/8 and FcyRIIA.
modulate of IgG effector functions. Indeed, application of soluble glycosyl-transferases could reduce autoantibody-induced inflammation in models of arthritis and nephrotoxic nephritis (133). However, it remains to be determined whether these very promising findings are exclusively due to IgG glycan modulation or the result of a more complex alteration of multiple glycan structures.

Sialic acid residues have recently been reported to contribute to another mechanism of FcγR regulation (Figure 1B).Prompted by the finding that CD18-deficient neutrophils show an enhanced recruitment to IgG-coated endothelium (134) and that an SNP in the CD18 integrin Mac-1 (rs1143679) is a risk factor for SLE (135), Saggu et al. investigated the interaction between FcγRIIA and Mac-1 on the cell surface. The authors convincingly show that the extracellular portion of Mac-1 in its inactive bend configuration interacts with sialylated FcγRIIA on resting neutrophils and thereby lowers the affinity of the receptor for IgG (40). Interestingly, once the interaction between FcγRIIA and IgG is sufficiently strong to overcome this increased activation threshold, Mac-1 assists FcγRIIA to induce cell spreading (136). This study provides a mechanistic explanation for the observation made earlier that FcγRIIA appears to have a lower affinity for IgG on resting neutrophils than on pre-activated ones.

Other molecules have been suggested to interact and modulate FcγRIIA activity. These include the ITIM-containing CD300a that can be rapidly mobilized from an intracellular pool to the surface of peripheral blood neutrophils following stimulation. Co-engagement of CD300a and FcγRIIA reduced FcγRIIA-dependent activation in an in vitro system (137) (Figure 1C). Furthermore, two plasma proteins produced in the liver during the acute phase of inflammations were described to interact with FcγRIIA (and FcγRIIB), the C-reactive protein (CRP) and the serum amyloid P (SAP) component (138, 139). CRP preferentially interacts with the FcγRIIA-R131-allele and can act like an opsonin, triggering the uptake of CRP-coated particles (140) (Figure 1D). Interestingly, IgG ICs can reduce CRP binding to FcγRIIA, whereas the reverse is not true (141). SAP was similarly described to act as an opsonin that could enhance phagocytosis via FcγRs (139). Additionally, it was described to reduce neutrophil adhesion by binding to FcγRIIA (142). Whether SAP binding can regulate IgG-dependent FcγRIIA activation remains however to be determined.

Another possibility to modulate FcγR-induced cell activation is to regulate receptor availability on the cell surface. This can be achieved by receptor internalization (8, 90, 93), translocation from intracellular storage compartments to the cell surface (22), or shedding of the extracellular portion of the FcγR. This latter phenomenon is best documented for FcγRIIIB, which is rapidly and efficiently cleaved from the cell surface following neutrophil stimulation (143), and during neutrophil apoptosis (34, 35). The main protease responsible for this ectodomain shedding appears to be ADAM17 (A Desintegrin and Metalloprotease-17) (144) that is rapidly activated following multiple cell stimulating pathways, such as FcγR/CR-dependent phagocytosis or stimulation with IMLP or PMA (145) (Figure 1E). ADAM17 activation appears to require activation of caspase 8 and mitochondrial ROS production (146). Supporting an important role for the regulation of cell activation by ADAM17, ADAM17 deficiency in humans has been associated with severe inflammatory disorders of the skin and the gut, resulting in recurrent sepsis and poor survival (147, 148).

Similar to the ectodomain shedding of FcγRIIIB, reduction of surface FcγRIIA on Langerhans cells and activated neutrophils has been described (39, 149). These initial observations have recently gained attention by the demonstration that TLR-induced activation resulted in the cleavage of extracellular FcγRIIA on the neutrophil surface, thus removing the N-terminal portion of the receptor (150) (Figure 1F). This cleavage has functional consequences for the neutrophils. It reduces their phagocytic activity, while augmenting their propensity to produce NETs, thereby supporting the concept that phagocytosis and NETosis could be neutrophil effector functions that oppose each other, as had been suggested by the finding that NETosis was reduced when microbes where small enough to be phagocytized (151).

Recently, neutrophils from SLE patients and especially their low-density granulocytes that were reported to spontaneously release NETs (152) seem to express less "full-length" FcγRIIA than neutrophils from healthy donors (150). This might explain why neutrophils from SLE patients fail to efficiently clear circulating ICs and are NET-prone (153). The cleavage of the N-terminal portion of FcγRIIA involves a PI3K-dependent production of ROS and seems to be mediated by the serin-protease furin (150); the exact mechanism of its action, however, as well as the fate and role of the N-terminal fragment of FcγRIIA following cleavage remains to be discovered. Similarly, questions on the stability, function, and possibly altered affinity of the shortened membrane-bound FcγRIIA justify further research in this area.

Finally, it has been suggested that FcγRIIIB could represent an efficient modulator of FcγRIIA activity in neutrophils. Indeed, the weakly signaling FcγRIIIB predominates FcγRIIA expression on resting neutrophils. Furthermore, CD16B extends out further from the cell surface membrane (154, 155), implying that FcγRIIIB is likely to capture circulating immune complexes, thus competing with and preventing FcγRIIA–IgG interactions. The picture is very different with regard to activated neutrophils that, through FcγRIIIB ectodomain shedding, grant access to cell-activating FcγRIIA (154).

CROSS-TALK OF NEUTROPHILS AND B CELLS

Collectively, these studies underline the critical involvement of IgGs in the modulation of neutrophil activity. Indeed, IgGs through FcγRs render neutrophils capable to act to threats to the host in an antigen-specific manner, but are also the trigger for tissue damage if autoantigens are being targeted. Interestingly, there is accumulating evidence that neutrophils are not mere effector cells of the immune system, but actively shape and modulate immune responses through interactions with other cells and the release of mediators. In the context of
IgG-dependent immunity, their recently described interactions with B cells are of particular interest.

Data from patients receiving G-CSF suggested that neutrophils can communicate with B cells through production of BAFF (B cell-activating factor) (156), a molecule known to sustain B cell survival and responsiveness (157, 158). Similarly, APRIL (A Proliferation Inducing Ligand) was suggested to be an important survival proliferation factor for human B cells, which additionally drives class-switching reactions (159–161). Neutrophils constitutively secrete APRIL (162), but circulating neutrophils fail to directly activate B cells. Upon infection, neutrophil-derived APRIL is retained by heparan sulfate proteoglycans in mucosal tissues, thereby creating a niche for local plasma cell survival and sustained antibody production (163). Similarly, it has been reported that diffuse large B cell lymphoma secretes chemokines to recruit APRIL-producing blood neutrophils to the tumor (162) and that high APRIL concentrations in tumors are correlated with decreased patient survival rates (164). In SLE, neutrophils interact with B cells in many different ways. SLE neutrophils were reported to show increased expression of BAFF, APRIL, and IFN-α that fuels B cell development and autoantibody production in the bone marrow. In the circulation, SLE neutrophils secrete increased amounts of IL-6 upon IFN-α stimulation that supports survival and maturation of B cells and plasma blasts (165). Concomitantly, they are also NET-prone and release LL37-DNA complexes that trigger polyclonal B cell activation via TLR9, giving rise to more NET-specific autoantibodies (166).

Neutrophils can also be found in multiple locations of the spleen, including the peri follicular zone, around the marginal zone (MZ) and the red pulp (167–170). Their exact role in each of these compartments is not fully understood. In the spleen, a specialized subset of neutrophils has been described that has the capacity to provide B cell support. These “B cell helper neutrophils” (NBH) are located around the MZ of healthy human donors and express high levels of the B cell- stimulating cytokines BAFF, APRIL, and IL-21 in response to microbial stimuli and thereby provide帮助 to MZ B cells to trigger antibody production against T cell-independent antigens (169). In patients with severe congenital neutropenia (SCN), CD27+ IgDlow circulating MZ B cells and levels of IgM, IgG, and IgA antibodies against T cell-independent antigens were less abundant than in healthy subjects (169). Contradicting this report, no NBH could be identified in spleen samples from organ transplant donors (171); also, similar numbers of CD27+ IgD+ memory B cells were reported in patients suffering from chronic idiopathic neutropenia and healthy subjects (172).

In addition to BAFF and APRIL, Pentraxin3 (PTX3) has been proposed to be a neutrophil-derived factor that supports B cell functions (173). PTX3 is stored in secondary granules of neutrophils and released upon stimulation with Toll-like receptor agonists (174). PTX3 binds to MZ B cells and enhances the secretion of class-switched IgG in the presence of BAFF (173).

The capacity of neutrophils to secrete B cell-stimulating factors enables them to directly interact with the adaptive immune system and shape antibody responses, which, in turn, can trigger potent neutrophil effector functions. This underlines the complexity of our immune system and the multiple layers of regulation that are at play to efficiently protect us from external threats.

CONCLUDING REMARKS

Collectively, the discussed literature exemplifies how our understanding of neutrophils has evolved from their early descriptions as simple first-line defense cells, equipped with powerful weapons to defend the host but unable to differentiate between different threats, to portrayals of cells capable of tailoring their responses according to their environment. We now appreciate that neutrophils interact with various other cell types, integrate complex stimuli, and cooperate with other players of the immune system to fine-tune their responses. The role and regulation of FcγR on neutrophils is not an exception to this rule. Early reports frequently suggested that IgG ICs had very strong neutrophil-activating capacities, but more recently, a much more detailed picture has been drawn, taking into account the size, solubility, composition, and location of ICs. Furthermore, IgG enables neutrophils to function as antigen-specific cells; at the same time, accumulating evidence suggest that neutrophils in turn tune the activity of (at least some) B cells to regulate antibody production. Much remains to be discovered and hopefully new techniques will allow us to unravel previously unappreciated functions of neutrophils and revise others. We are looking forward to hearing more about these exciting cells.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This work was supported by a Jeunes Chercheurs/Jeunes Chercheurs grant from the Agence National de la Recherche (ANR-16-CE15-0012-01). YW is part of the Pasteur–Paris University (PPU) International Ph.D Program. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 665807, and from the Labex Milieu Intérieur, Institut Pasteur. FJ is an employee of CNRS (Centre national de la recherche scientifique).

ACKNOWLEDGMENTS

We are grateful to Kasia Kready for critical reading of the manuscript.
REFERENCES

1. Ella K, Csepanty-Komi R, Kaldi K. Circadian regulation of human peripheral neutrophils. Brain Behav Immun. (2016) 57:209–1. doi: 10.1016/j.bbi.2016.04.016

2. Adrover JM, Del Fresno C, Crainiciu G, Cuartero MI, Casanova-Acebes M, Weiss LA, et al. A Neutrophil timer coordinates immune defense and vascular protection. Immunity. (2019) 50390–402.e310. doi: 10.1016/j.immunity.2019.01.002

3. Ilma B, Hergovich N, Stohlwetz P, Eichler HG, Bauer P, Wagner OF. Circadian variation of granulocyte colony stimulating factor levels in man. Br J Haematol. (1999) 106:368–70. doi: 10.1046/j.1365-2141.1999.01543.x

4. Filetder TM, Cronkite EP, Killmann SA, Bond VP. Granulocytopenia. II. Emergence and pattern of labeling of neutrophilic granulocytes in humans. Blood. (1964) 24:683–700.

5. Pillay J, den Braber I, Vergeer C, Kwast LM, de Boer RJ, Borghans JA, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. (2010) 116:625–7. doi: 10.1182/blood-2010-01-259028

6. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin AE. Neutrophil mobilization and clearance in B lymphocytes. Science. (2016) 353:209–14. doi: 10.1126/science.aag4840

7. Furze RC, Rankin SM. Neutrophil Fc receptors and reactive oxygen species (ROS) released during phagocytosis may inhibit the function of B lymphocytes. Immunol. (2016) 232:59–71. doi: 10.1016/j.immuni.2019.01.002

8. Teillaud JL, et al. CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem J. (2006) 393(Pt 1):351–9. doi: 10.1042/BJ20050129

9. Jost CR, Huizinga TW, de Goede R, Fransen JA, Tettero PA, Daha MR, et al. Intracellular localization and de novo synthesis of FcRIII in human neutrophil granulocytes. Blood. (1990) 75:144–51.

10. Tosi M, Zakem H. Surface expression of Fc gamma receptor III (CD16) on chemotactic-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments. J Clin Invest. (1992) 90:462–70. doi: 10.1172/JCI115882

11. Huizinga TW, Dolman KM, van der Linden NJ, Kleijer M, Nuijens JH, von dem Borne AE, et al. Phosphatidylinositol-linked FcRII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst. J Immunol. (1990) 144:1432–7.

12. Kimberly RP, Ahlistrom JW, Click ME, Edberg JC. The glycosyl phosphatidylinositol-linked Fc gamma receptors mediate transmembrane signaling events distinct from Fc gamma RI. J Exp Med. (1999) 180:1239–55. doi: 10.1084/jem.171.1.1239

13. Kocher M, Siegel ME, Edberg JC, Kimberly RP. Cross-linking of Fc gamma receptor Ia and Fc gamma receptor IIb induces different proadhesive phenotypes on human neutrophils. J Immunol. (1997) 159:3940–8.

14. Coxaon A, Bullere X, Knight S, Sethi S, Wakelin MW, Stavrakis G, et al. Fc gamma RI mediates neutrophil recruitment to immune complexes. A mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity. (2001) 14:693–704. doi: 10.1016/S1074-7613(01)00150-9

15. Chen K, Nishi H, Travers S, Tsibou N, Martinod K, Wagner DD, et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood. (2012) 120:4241–31. doi: 10.1182/blood-2011-01-371013

16. Garcia-Garcia E, Nieto-Castaneda G, Ruiz-Saldana M, Mora N, Rosales C. FcgammaRIIA and FcgammaRIIB mediate neutral factor activation through separate signaling pathways in human neutrophils. J Immunol. (2009) 182:4547–56. doi: 10.4049/jimmunol.0801468

17. Lindorfer MA, KJ, Taylor RP. Interactions between the complement system and Fc receptors. In: Nimnjarjahn Ackerman FME, editor. Antibody Fc: Linking Adaptive and Innate Immunity. Philadelphia, PA: Elsevier (2014), p. 49–74. doi: 10.1016/B978-0-12-394802-1.00003-0

18. Zhou MJ, Lublin DM, Link DC, Brown EJ. Distinct tyrosine kinase activation and Triton X-100 insolubility upon Fc gamma RII or FcgammaRIIB ligation in human polymorphonuclear leukocytes. Implications for immune complex activation of the respiratory burst. J Biol Chem. (1995) 270:13535–60. doi: 10.1074/jbc.270.22.13535

19. Coxaon P, Rane MJ, Powell DW, Klein JB, McLeish KR. Differential mitogen-activated protein kinase stimulation by Fc gamma receptor Ia and Fc gamma receptor IIb determines the activation phenotype of human neutrophils. J Immunol. (2000) 164:6530–7. doi: 10.4049/jimmunol.164.12.6530

20. Hazan-Haley I, Seger R, Levy R. The requirement of both extracellular regulated kinase and p38 mitogen-activated protein kinase stimulation for stimulation of cytosolic phospholipase A2 activity by either FcgammaRIA or FcgammaRIIB in human neutrophils. A possible role for Pyk2 but not for the Grb2-Sos-Shc complex. J Biol Chem. (2000) 275:12416–23. doi: 10.1074/jbc.275.17.12416

21. Vonsebesl P, Homburg CH, Roos D, Verhoeven AJ. The anti-Fc gamma RII mAb 3G8 induces neutrophil activation via a cooperative actin of FcgammaRIIB and Fc gamma RIIA. J Innate Immun. (2017) 9:248–55. doi: 10.1186/s13011-016-0174-0

22. Huizinga TW, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AE. Soluble Fc gamma receptor III in human plasma originates from release by neutrophils. J Clin Invest. (1990) 86:416–23. doi: 10.1172/JCI14727

23. Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C, Hogg N. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RII) expression. J Immunol. (1994) 153:1234–63.

24. Telllaud JL, Bouchard C, Astier A, Telllaud C, Tartoue E, Micion J, et al. Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities. Immunomethods. (1994) 4:48–64. doi: 10.1006/immu.1994.1007
37. Esposito-Farese ME, Sautes C, de la Salle H, Latour S, Bieber T, de la Salle C, et al. Membrane and soluble Fc gamma RI/II/III modulate the antigen-presenting capacity of murine dendritic epidermal cells. J Immunol. (1995) 155:1725–36.

38. Galon J, Gauchat JF, Mazieres N, Spagnoli R, Lenterkus W, Lotze M, et al. Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol. (1996) 157:1184–92.

39. Nagarajan S, Venkiteswaran K, Anderson M, Sayed U, Zhu C, Selvaraj P. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood. (2000) 95:1069–77. Available online at: http://www.bloodjournal.org/content/95/3/1069-ss0-true

40. Saggu G, Okubo K, Chen Y, Vattepu R, Tsuboi N, Rosetti F, et al. Cis interaction between sialylated FcgammaRIIA and the alphal-domain of Mac-1 limits antibody-mediated neutrophil recruitment. Nat Commun. (2018) 9:5058. doi: 10.1038/s41467-018-07506-1

41. Crockett-Torabi E, Fantone JC. Soluble and insoluble immune complexes activate human neutrophil NADPH oxidase by distinct Fc gamma receptor-specific mechanisms. J Immunol. (1990) 145:3026–32.

42. Breduis RG, Figen CA, De Haas M, Kuijper EJ, Weening RS, Van de Winkel M, et al. Modifications of FcgammaRII polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. (1994) 83:624–30.

43. Unkeless JC, Shen Z, Lin CW, DeBeus E. Function of human Fc gamma RIIA and Fc gamma RIIB (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. (1995) 83:75–44. doi: 10.1044/1094-5333(95)00006-3

44. Tsuibo N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity. (2008) 28:833–46. doi: 10.1016/j.immuni.2008.04.013

45. Znyteck C, Schmitz J, Winkelgs G. (2013). Untouched isolation of functional unaffected neutrophils from whole blood within 20 minutes. Front Immunol. 2:621. doi: 10.3389/conf.fimmu.2013.02.00621

46. Calzetti F, Tamassia N, Arruda-Silva E, Gasperini S, Cassatella MA. The importance of being "pure" neutrophils. J Allergy Clin Immunol. (2017) 139:352–5;e356. doi: 10.1016/j.jaci.2016.06.025

47. Akerley WL, 3rd, Guyre PM, Davis BH. Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood. (1991) 77:607–15.

48. Persussi B, Dayton ET, Lazarus R, Fanning V, Trinchieri G. Immune interferon induces the receptor for monomeric IgG1 on human monocyte and myeloid cells. J Exp Med. (1983) 158:1092–113. doi: 10.1084/jem.158.4.1092

49. Schif DE, Rae J, Martin TR, Davis BH, Curnette JT. Increased phagocytic Fc gammaRIIa expression and improved Fc gamma receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. (1997) 90:3187–94.

50. Su K, Yang H, Li X, Li X, Gibson AW, Cafardi JM, et al. Expression profile of FgammaRIIB on leucocytes and its dysregulation in systemic lupus erythematosus. J Immunol. (2007) 178:3272–80. doi: 10.4049/jimmunol.178.3.3272

51. Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, Intronia M. Human neutrophils express low levels of FcgammaRIIa, which plays a role in PMN activation. Blood. (2003) 113:1395–405. doi: 10.1182/blood-2001-12-0053

52. Bruhns P, Jonsson F. Mouse and human FcR effector functions. Immunol Rev. (2015) 268:25–51. doi: 10.1111/imr.12350

53. Hundt M, Schubert J, de Haas M, Zielinska-Skowronek M, Schmidt RE. The loss of Fc gamma RIIB in paroxysmal nocturnal hemoglobinuria is functionally related by Fc gamma RII. Blood. (1994) 83:3574–80.

54. Guyre PM, Campbell AS, Kniffin WD, Fanger MW. Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors. J Clin Invest. (1990) 86:1892–6. doi: 10.1172/JCI14921

55. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood. (1991) 78:885–9.
in functional responses induced by priming with cytokines. Ann Rheum Dis. (2002) 61:13–9. doi: 10.1136/ard.61.1.13

74. Lauterbach M, O’Donnell P, Asano K, Mayadas TN. Role of TNF priming and adhesion molecules in neutrophil recruitment to intravascular immune complexes. J Leukoc Biol. (2008) 83:1423–30. doi: 10.1189/jlb.0607421

75. Higurashi S, Maeda Y, Suzuki M, Kobrabi I, Masusho Y. Both the Fab and Fc domains of IgG are essential for ROS emission from TNF-alpha-primed neutrophils by IVIG. Biochem Biophys Res Commun. (2012) 417:794–9. doi: 10.1016/j.bbrc.2012.11.038

76. Jönsson F, Mancardi DA, Zhao W, Iannascoli B, Khun H, et al. Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood. (2012) 119:2533–44. doi: 10.1182/blood-2011-07-36334

77. Su K, Wu J, Edberg JC, Li X, Ferguson P, Kimberley RP. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIB alters receptor expression and associates with autoimmunity. II. differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J Immunol. (2004) 172:7192–9. doi: 10.4049/jimmunol.172.11.7192

78. Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, et al. Loss of function of a lupus-associated FcgammaRIIB polymorphism through exclusion from lipid rafts. Nat Med. (2005) 11:1056–8. doi: 10.1038/nm1288

79. Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzel G, Lauterbach M, O’Donnell P, Asano K, Mayadas TN. Role of TNF priming and adhesion molecules in neutrophil recruitment to intravascular immune complexes. J Leukoc Biol. (2008) 83:1423–30. doi: 10.1189/jlb.0607421

80. Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis of human Fc receptor IIa (CD32) polymorphism: disease association with recurrent bacterial respiratory tract infections. J Immunol. (2003) 172:1792–5. doi: 10.4049/jimmunol.172.1.19

81. Sanders LA, van de Winkel JG, Rijkers GT, Voorhorst-Oogink MM, de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE. Neutrophil FcgammaRIIA induces anaphylactic and allergic reactions. J Exp Med. (1995) 172:7186–91. doi: 10.1084/jem.172.17.4009

82. Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzel G, Lauterbach M, O’Donnell P, Asano K, Mayadas TN. Role of TNF priming and adhesion molecules in neutrophil recruitment to intravascular immune complexes. J Leukoc Biol. (2008) 83:1423–30. doi: 10.1189/jlb.0607421
autoimmune diseases: a meta-analysis. Inflamm Res. (2015) 64:983–1.
doi: 10.1007/s00011-015-0882-1.

110. Zhu XW, Wang Y, Wei YH, Zhao PP, Wang XQ, Rong JJ, et al. Comprehensive assessment of the association between FCGRs polymorphisms and the risk of systemic lupus erythematosus: evidence from a meta-analysis. Scand J Immunol. (2016) 93:95.
doi: 10.1111/sji.13167.

111. Clark MR, Liu L, Clarkson SB, Ory PA, Goldstein IM. An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus. J Clin Invest. (1990) 86:341–6. doi: 10.1172/JCI14706.

112. Li X, Ptascek TS, Brown EE, Edberg JC. Fcgamma receptors: Structure, function and role as genetic risk factors in SLE. Genes Immun. (2009) 10:380–9. doi: 10.1038/gen.2009.35.

113. Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, et al. Publisher note. Frontiers in Immunology | www.frontiersin.org 12 August 2019 | Volume 10 | Article 1968

120. Niellen MM, van Schaardenburg D, Reeskink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. (2004) 50:380–6. doi: 10.1002/art.20018.

121. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, et al. Clinical criteria for systematic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. (2007) 56:2344–51. doi: 10.1002/art.22665.

122. Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruehbeiser S, Amara K, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun. (2015) 6:6561. doi: 10.1038/ncomms7561.

123. Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. (2015) 74:234–41. doi: 10.1136/annrheumdis-2013-203565.

124. Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. (2018) 172564-577.e513. doi: 10.1016/j.cell.2017.11.041.

125. Tang T, Rosenkranz A, Assmann KJ, Goodman MJ, Gutierrez-Ramos JC, Carroll MC, et al. A role for Mac-1 (CD11b/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J Exp Med. (1997) 186:1853–63. doi: 10.1084/jem.186.11.1853.

126. Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, Gilkeson GS, et al. A nonsynergy functional variant in integrin-alpha(M)(E) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet. (2008) 40:152–4. doi: 10.1038/ng.71.

127. SL. Jones EB (1996). Functional Cooperation Between Fcg Receptors and Complement Receptors in Phagocytes. Austin: R.G. Landes.

128. Alvarez Y, Tang X, Coligan J, Borrego F. The CD300a (IRp60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Mol Immunol. (2008) 45:253–8. doi: 10.1016/j.molimm.2006.09.005.

129. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leucocytes is fcgamma receptor II. J Exp Med. (1999) 190:585–90. doi: 10.1084/jem.190.4.585.

130. Bharadwaj D, Mold C, Markham E, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol. (2001) 166:6735–41. doi: 10.4049/jimmunol.166.11.6735.

131. Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest. (2000) 105:369–76. doi: 10.1172/JCI7817.

132. Zeller JM, Kubak BM, Gewurz H. Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunology. (1989) 67:51–5.

133. Cox N, Pilling D, Gomer RH. Distinct Fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibroclyte differentiation. J Immunol. (2004) 173:1701–8. doi: 10.4049/jimmunol.173.6.1701.

134. Galon J, Moldovan I, Galinha A, Provost-Marlio MA, Kauwertz H, Roman-Roman S, et al. Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol. (1999) 29:2101–7. doi: 10.1002/eji.10459.

135. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol. (2001) 166:6735–41. doi: 10.4049/jimmunol.166.11.6735.

136. Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest. (2000) 105:369–76. doi: 10.1172/JCI7817.

137. Zeller JM, Kubak BM, Gewurz H. Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunology. (1989) 67:51–5.

138. Cox N, Pilling D, Gomer RH. Distinct Fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibroclyte differentiation. J Immunol. (2004) 173:1701–8. doi: 10.4049/jimmunol.173.6.1701.

139. Galon J, Moldovan I, Galinha A, Provost-Marlio MA, Kauwertz H, Roman-Roman S, et al. Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol. (1999) 29:2101–7. doi: 10.1002/eji.10459.

140. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leucocytes is fcgamma receptor II. J Exp Med. (1999) 190:585–90. doi: 10.1084/jem.190.4.585.

141. Bharadwaj D, Mold C, Markham E, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol. (2001) 166:6735–41. doi: 10.4049/jimmunol.166.11.6735.

142. Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest. (2000) 105:369–76. doi: 10.1172/JCI7817.

143. Zeller JM, Kubak BM, Gewurz H. Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunology. (1989) 67:51–5.

144. Cox N, Pilling D, Gomer RH. Distinct Fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibroclyte differentiation. J Immunol. (2004) 173:1701–8. doi: 10.4049/jimmunol.173.6.1701.

145. Galon J, Moldovan I, Galinha A, Provost-Marlio MA, Kauwertz H, Roman-Roman S, et al. Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol. (1999) 29:2101–7. doi: 10.1002/eji.10459.
154. Selvaraj P, Fifadara N, Nagarajan S, Cimino A, Wang G. Functional characterization of neutrophils in the pathogenesis and manifestations of systemic lupus erythematosus. *Hum Pathol.* (2013) 44:923–8. doi: 10.1016/j.humpath.2013.02.010

155. de la Salle C, Esposito-Farase ME, Bieber T, Moncuit J, Morales M, Wellenberg A, et al. Release of soluble Fc gamma RI/CD32 molecules by human langerhans cells: a subtle balance between shedding and secretion? *J Invest Dermatol.* (1992) 99:155–7. doi: 10.1111/1523-1747.ep12668250

156. Branzik N, Lobojemskas A, Harden SE, Wang Q, Gutierrez MG, Brown GD, et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. *Nat Immunol.* (2014) 15:1017–25. doi: 10.1038/ni.2987

157. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. *J Immunol.* (2010) 184:3284–97. doi: 10.4049/jimmunol.0902199

158. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. *Nat Rev Rheumatol.* (2011) 7:691–9. doi: 10.1038/nrrheum.2011.132

159. Scapini P, Bazzoni F, Cassatella MA. Regulation of B-cell-activating factor (BAFF) expression and its functional role on human neutrophil Fc gamma receptors. *Immunol Res.* (2004) 29:219–30. doi: 10.1385/IR:29:1-3:219

160. Salzer U, Neumann C, Thiel J, Woellner C, Pan-Hammarstrom Q, Lougaris S, et al. Release of soluble Fc gamma RII/CD32 molecules by neutrophils following exposure to BAFF-secreting cells. *J Exp Med.* (2017) 214:1333–50. doi: 10.1084/jem.20161621

161. Gustafson CE, Higbee D, Yeckes AR, Wilson CC, De Zoeten EF, Jedlicka P, et al. Limited expression of APRIL and its receptors prior to intestinal Iga plasma cell development during human infancy. *Mucosal Immunol.* (2014) 7:467–77. doi: 10.1038/mi.2013.64

162. Gustafson CE, Higbee D, Yeckes AR, Wilson CC, De Zoeten EF, Jedlicka P, et al. Limited expression of APRIL and its receptors prior to intestinal Iga plasma cell development during human infancy. *Mucosal Immunol.* (2014) 7:467–77. doi: 10.1038/mi.2013.64

163. Huard B, McKee T, Bosshard C, Duraul S, Matthes T, Myit S, et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. *J Clin Invest.* (2008) 118:2887–95. doi: 10.1172/JCI33760

164. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. *Blood.* (2007) 109:331–8. doi: 10.1182/blood-2006-02-018000

165. Zimmermann M, Arruda-Silva F, Bianchettio-Aguilera F, Finotti G, Calzetti F, Scapini P, et al. IFN alpha enhances the production of IL-6 by human neutrophils activated via TLR8. *Sci Rep.* (2016) 6:19674. doi: 10.1038/srep19674

166. Gestermann N, Di Domizio J, Lande R, Demaria O, Frasca L, Feldmeyer L, et al. Netting neutrophils activate autoreactive B cells in lupus. *J Immunol.* (2018) 200:3364–71. doi: 10.4049/jimmunol.1700778

167. Nolte MA, Hoen EN, van Stijn A, Kralg G, Mebius RE. Isolation of the intact human white pulp. Quantitative and qualitative analysis of the cellular composition of the splenic compartments. *Eur J Immunol.* (2000) 30:626–34. doi: 10.1002/1521-4141(200002)30:2<626::AID-IMMU626>3.0.CO;2-H

168. Steiniger B, Barth P. Microanatomy and function of the spleen. Adv Anat Embryol Cell Biol. (2000) 151:1–101. doi: 10.1007/978-3-642-57088-9_1

169. Puga I, Gols M, Barra CM, He B, Cassis L, Gentile M, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. *Nat Immunol.* (2011) 13:170–80. doi: 10.1038/ni.2194

170. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. Screening of functional and positional candidate genes in families with common variable immunodeficiency. *BMC Immunol.* (2008) 9:3. doi: 10.1186/1471-2172-9-3

171. Nagelkerke SQ, aan de Kerk DJ, Jansen MH, van den Berg TK, Kuijpers A, Grommisch D, et al. Limited expression of APRIL and its receptors prior to intestinal Iga plasma cell development during human infancy. *Mucosal Immunol.* (2014) 7:467–77. doi: 10.1038/mi.2013.64

172. Mavroudi I, Eliopoulos AG, Pontikoglou C, Damianaki A, Koutala H, et al. Immunoglobulin and B-cell disturbances in patients with chronic idiopathic neutropenia. *Clin Immunol.* (2017) 183:75–81. doi: 10.1016/j.clim.2017.07.009

173. Chorny A, Casas-Recasens S, Sintes J, Shan M, Polentarutti N, Garcia-Escudero R, et al. The soluble pattern recognition receptor PTX3 links the humoral pattern recognition receptor PTX3 links to humoral innate and adaptive immune responses by helping marginal zone B cells. *J Exp Med.* (2016) 213:2167–85. doi: 10.1084/jem.20150282

174. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. *J Exp Med.* (2007) 204:793–804. doi: 10.1084/jem.20061301

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.